ES2380248T3 - Regulación de la actividad de las proteinas por acetilación reversible - Google Patents

Regulación de la actividad de las proteinas por acetilación reversible Download PDF

Info

Publication number
ES2380248T3
ES2380248T3 ES07809490T ES07809490T ES2380248T3 ES 2380248 T3 ES2380248 T3 ES 2380248T3 ES 07809490 T ES07809490 T ES 07809490T ES 07809490 T ES07809490 T ES 07809490T ES 2380248 T3 ES2380248 T3 ES 2380248T3
Authority
ES
Spain
Prior art keywords
acecs2
polypeptide
sirt3
agent
activity
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
ES07809490T
Other languages
English (en)
Spanish (es)
Inventor
Bjoern Schwer
Eric Verdin
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
J David Gladstone Institutes
Original Assignee
J David Gladstone Institutes
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by J David Gladstone Institutes filed Critical J David Gladstone Institutes
Application granted granted Critical
Publication of ES2380248T3 publication Critical patent/ES2380248T3/es
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/502—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing non-proliferative effects
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Hematology (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Molecular Biology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Diabetes (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Organic Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Microbiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Obesity (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Toxicology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
ES07809490T 2006-06-12 2007-06-12 Regulación de la actividad de las proteinas por acetilación reversible Active ES2380248T3 (es)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US81327506P 2006-06-12 2006-06-12
US813275P 2006-06-12
US761198 2007-06-11
US11/761,198 US8518635B2 (en) 2006-06-12 2007-06-11 Regulation of protein activity by reversible acetylation
PCT/US2007/013804 WO2007149270A2 (en) 2006-06-12 2007-06-12 Regulation of protein activity by reversible acetylation

Publications (1)

Publication Number Publication Date
ES2380248T3 true ES2380248T3 (es) 2012-05-09

Family

ID=38833973

Family Applications (1)

Application Number Title Priority Date Filing Date
ES07809490T Active ES2380248T3 (es) 2006-06-12 2007-06-12 Regulación de la actividad de las proteinas por acetilación reversible

Country Status (8)

Country Link
US (1) US8518635B2 (https=)
EP (1) EP2029731B1 (https=)
JP (1) JP2009542195A (https=)
AT (1) ATE543902T1 (https=)
AU (1) AU2007261561B2 (https=)
CA (1) CA2654458A1 (https=)
ES (1) ES2380248T3 (https=)
WO (1) WO2007149270A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004022580A2 (en) 2002-09-09 2004-03-18 Dana-Farber Cancer Institute, Inc. Bh3 peptides and method of use thereof
EP2008106A2 (en) 2006-03-31 2008-12-31 Dana-Farber Cancer Institute Methods of determining cellular chemosensitivity
HK1213046A1 (zh) 2012-09-19 2016-06-24 Dana-Farber Cancer Institute, Inc. 動態bh3分析
CA2922503C (en) 2013-09-19 2021-10-26 Dana-Farber Cancer Institute, Inc. Methods of bh3 profiling
AU2016253957C1 (en) 2015-04-27 2021-04-01 Dana-Farber Cancer Institute, Inc. High throughput BH3 profiling: a rapid and scalable technology to BH3 profile on low numbers of cells
JP7589159B2 (ja) 2019-02-26 2024-11-25 デイナ ファーバー キャンサー インスティチュート，インコーポレイテッド ライブセルイメージング（ｌｉｖｅ ｃｅｌｌ ｉｍａｇｉｎｇ）動的ＢＨ３プロファイリング
WO2023122805A1 (en) 2021-12-20 2023-06-29 Vestaron Corporation Sorbitol driven selection pressure method

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US82668A (en) * 1868-09-29 Thomas b
US120008A (en) * 1871-10-17 Improvement in apparatus for feeding pulverized fuel to metallurgical and other furnaces
JP2001149081A (ja) 1999-11-29 2001-06-05 Cyclex Co Ltd 脱アセチル化酵素の活性測定方法、並びにこれら酵素の阻害剤もしくは促進剤のスクリーニング方法
US20020120008A1 (en) 2000-06-29 2002-08-29 Seymour Benzer Life extension of drosophila by a drug treatment
US7241743B2 (en) 2001-06-15 2007-07-10 The Trustees Of Columbia University In The City Of New York Sir2α-based therapeutic and prophylactic methods
US7488587B2 (en) 2001-06-19 2009-02-10 The J. David Gladstone Institutes Histone deacetylase and methods of use thereof
CA2453195A1 (en) 2001-07-06 2003-01-16 Leonard Guarente Sir2 activity
US7351542B2 (en) 2002-05-20 2008-04-01 The Regents Of The University Of California Methods of modulating tubulin deacetylase activity
CA2417033A1 (en) 2003-01-23 2004-07-23 Paul Kerr External support structure for use in the transporting of manufactured houses
US7272713B1 (en) 2003-10-22 2007-09-18 Symantec Corporation Controlling file operations
US7485416B2 (en) 2003-12-23 2009-02-03 The Regents Of The University Of California Screening methods for the identification of agents that inhibit SIRT1 Tat deacetylase activity

Also Published As

Publication number Publication date
US8518635B2 (en) 2013-08-27
WO2007149270A9 (en) 2008-03-06
US20090061015A1 (en) 2009-03-05
EP2029731A4 (en) 2009-10-21
AU2007261561B2 (en) 2013-02-28
WO2007149270A2 (en) 2007-12-27
WO2007149270A3 (en) 2008-10-30
JP2009542195A (ja) 2009-12-03
CA2654458A1 (en) 2007-12-27
EP2029731B1 (en) 2012-02-01
AU2007261561A1 (en) 2007-12-27
EP2029731A2 (en) 2009-03-04
ATE543902T1 (de) 2012-02-15

Similar Documents

Publication Publication Date Title
Nguyen et al. The MARCHF6 E3 ubiquitin ligase acts as an NADPH sensor for the regulation of ferroptosis
Borra et al. Conserved enzymatic production and biological effect of O-acetyl-ADP-ribose by silent information regulator 2-like NAD+-dependent deacetylases
ES2380248T3 (es) Regulación de la actividad de las proteinas por acetilación reversible
Srinivasan et al. Extracellular 4′-phosphopantetheine is a source for intracellular coenzyme A synthesis
Strebhardt et al. Targeting polo-like kinase 1 for cancer therapy
Xie et al. Silencing of EEF2K (eukaryotic elongation factor-2 kinase) reveals AMPK-ULK1-dependent autophagy in colon cancer cells
Casey et al. Identification of a mutation in LARS as a novel cause of infantile hepatopathy
Pereira et al. IMPACT, a protein preferentially expressed in the mouse brain, binds GCN1 and inhibits GCN2 activation
ES2415665T3 (es) Procedimientos de cribado usando c-abl, fyn y sky en combinación con la proteína tau
Botta et al. MBNL142 and MBNL143 gene isoforms, overexpressed in DM1-patient muscle, encode for nuclear proteins interacting with Src family kinases
US20110287026A1 (en) Sirt4 and uses thereof
Shaik et al. Low intensity shear stress increases endothelial ELR+ CXC chemokine production via a focal adhesion kinase-p38β MAPK-NF-κB pathway
CN101490250A (zh) 通过可逆乙酰化调节蛋白质活性
Reynolds-Peterson et al. Heparan sulfate proteoglycans regulate autophagy in Drosophila
Natale et al. Inhibition of zDHHC7-driven protein S-palmitoylation prevents cognitive deficits in an experimental model of Alzheimer’s disease
CA2753897A1 (en) Methods for modulating metabolic and circadian rhythms
Liu et al. Fat body-specific reduction of CTPS alleviates HFD-induced obesity
US20150024955A1 (en) Methods of Identifying Modulators of Dephosphorylation of Histone Deacetylase
Zhang et al. Oncometabolite 5-IP7 inhibits inositol 5-phosphatase to license E-cadherin endocytosis
Sha et al. The protection of UCK2 protein stability by GART maintains pyrimidine salvage synthesis for HCC growth under glucose limitation
US20090156523A1 (en) Methods and compositions for modulating foxo1 activity and insulin signaling
Wang et al. Ser71 phosphorylation inhibits actin-binding of profilin-1 and its apoptosis-sensitizing activity
Gamper et al. Regulation of Dictyostelium protein-tyrosine phosphatase-3 (PTP3) through osmotic shock and stress stimulation and identification of pp130 as a PTP3 substrate
Liao et al. The AHCY–adenosine complex rewires mRNA methylation to enhance fatty acid biosynthesis and tumorigenesis
US20070026431A1 (en) Modulation of MAPK-mediated phosphorylation and/or FBXW8-mediated ubiquitinylation of cyclin D1 in modulation of cellular proliferation